Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F3591 mutation of BCR-ABL oncogene

• Autorzy: Baranska M , Lewandowski K , Gniot M , Iwola M , Lewandowska M , Komarnicki M
• Języki publikacji: EN

Abstrakty

EN

Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.

Słowa kluczowe

EN

dasatinib; treatment; imatinib resistance; nilotinib resistance; chronic myeloid leukemia; patient; F3591 mutation; BCR-ABL oncogene; kinase inhibitor

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2008
• Tom: 49
• Numer: 2
• Opis fizyczny: p.201-203,fig.,ref.

Twórcy

autor

Baranska M

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

autor

Lewandowski K

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

autor

Gniot M

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

autor

Iwola M

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

autor

Lewandowska M

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

autor

Komarnicki M

• Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland

Bibliografia

• Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. 2007. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109: 4143-4150.
• Jakubowska J, Czyż M, 2006. Alternatywne dla STI571 inhibitory kinazy Ber-Abl. Postępy Hig Med. Dośw. 60: 697-706.
• Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. 2007. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109: 5143-5150.
• Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, et al. 2004. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome- positive chronic phase chronic myeloid leukemia. Blood 103: 2873-2878.
• O’Hare T, Eide CA, Deininger MWN, 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249.
• Quintás-Cardama A, Kantarjian H, Jones D, Nicaise C, O’Brien S, et al. 2007. Dasatinib (BMS-354825) is active in Philadephia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497-499.
• Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD, 2007. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study. Blood 109: 5011-5015.
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. 2007. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541.
• Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, et al. 2006. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistance ABL mutants. Cancer Res 66: 5790-5797.
• von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel Ch, Duyster J, 2006. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328-1333.
• Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD, 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Can 94: 1765-1769.